**Back 1981** Back DJ, Bates M, Breckenridge AM, Hall JM, MacIver M, Orme ML, Park BK, Rowe PH. The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. Contraception. 1981 Mar;23(3):229-39. doi: 10.1016/0010-7824(81)90045-7. 

**Back 1987** Back DJ, Grimmer SF, Rogers S, Stevenson PJ, Orme ML. Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. Contraception. 1987 Oct;36(4):471-9. doi: 10.1016/0010-7824(87)90095-3. 

**Bayer 2009** Bayer Healthcare Pharmaceutics. Plan-B One Step [package insert and label information]. US Food and Drug Administration (2009).

**Cicali 2021** Cicali B, Lingineni K, Cristofoletti R, Wendl T, Hoechel J, Wiesinger H, Chaturvedula A, Vozmediano V, Schmidt S. Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling. CPT Pharmacometrics Syst Pharmacol. 2021 Jan;10(1):48-58. doi: 10.1002/psp4.12572. 

**Goebelsmann 1986** Goebelsmann U, Hoffman D, Chiang S, Woutersz T. The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive. Contraception. 1986 Oct;34(4):341-51. doi: 10.1016/0010-7824(86)90087-9. 

**Humpel 1978** Humpel M, Wendt H, Pommerenke G, Weiss C, Speck U. Investigations of pharmacokinetics of levonorgestrel to specific consideration of a possible first-pass effect in women. Contraception. 1978 Mar;17(3):207-20. doi: 10.1016/0010-7824(78)90012-4. 

**Johansson 2002** Johansson E, Brache V, Alvarez F, Faundes A, Cochon L, Ranta S, Lovern M, Kumar N. Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy women. Hum Reprod. 2002 Jun;17(6):1472-6. doi: 10.1093/humrep/17.6.1472. 

**Kook 2002** Kook K, Gabelnick H, Duncan G. Pharmacokinetics of levonorgestrel 0.75 mg tablets. Contraception. 2002 Jul;66(1):73-6. doi: 10.1016/s0010-7824(02)00321-9.

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531. doi: 10.1002/psp4.12134. Epub 2016 Oct 19. 	

**Kives 2005** Kives S, Hahn PM, White E, Stanczyk FZ, Reid RL. Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. Contraception. 2005 Mar;71(3):197-201. doi: 10.1016/j.contraception.2004.09.009.

**Kuhnz 1994** Kuhnz W, Staks T, Jütting G. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. Contraception. 1994 Dec;50(6):563-79. doi: 10.1016/0010-7824(94)90014-0. 

**Li 1990** Li QG, Hümpel M. Serum protein binding characteristics of cyproterone acetate, gestodene, levonorgestrel and norethisterone in rat, rabbit, dog, monkey and man. J Steroid Biochem. 1990 Feb;35(2):319-26. doi: 10.1016/0022-4731(90)90291-y. 

**Menon 2016** Menon S, Riese R, Wang R, Alvey CW, Shi H, Petit W, Krishnaswami S. Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. Clin Pharmacol Drug Dev. 2016 Sep;5(5):336-42. doi: 10.1002/cpdd.270. 

**Natavio 2019** Natavio M, Stanczyk FZ, Molins EAG, Nelson A, Jusko WJ. Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. Contraception. 2019 May;99(5):306-311. doi: 10.1016/j.contraception.2019.01.003.

**NovoNordisk 2007** Novo Nordisk A/S, D. (2007). "A Double-Blind, Two Period Cross-Over, Single Centre Trial in Healthy Subjects Investigating the Influence on the Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Drug after Multiple Dose Administration of Liraglutide."

**Praditpan 2017** Praditpan P, Hamouie A, Basaraba CN, Nandakumar R, Cremers S, Davis AR, Westhoff CL. Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. Contraception. 2017 May;95(5):464-469. doi: 10.1016/j.contraception.2017.01.004.

**PK-Sim Ontogeny Database Version 7.3** ([https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf](https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf))	

**Rao 2011** Rao RM, Bansal K, Padhee K, Sathapathy A, Kochhar PS. Dissolution Enhancement Of Levonorgestrel By Micronization: Comparison with Commercial Product. Int J Pharmaceut Sci Rev Res. 2011; 8:32-34. 

**Schlender 2016** Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet. 2016 Dec;55(12):1573-1589. 	

**Tremblay 2001** Tremblay D, Gainer E, Ulmann A. The pharmacokinetics of 750 microg levonorgestrel following administration of one single dose or two doses at 12- or 24-h interval. Contraception. 2001 Dec;64(6):327-31. doi: 10.1016/s0010-7824(01)00276-1. 